The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Trial Profile

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs Empagliflozin (Primary) ; Linagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Feb 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 15 May 2017 Planned initiation date changed from 1 Jul 2017 to 1 Dec 2017.
    • 08 Dec 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top